基因治疗的非复制性简单疹病毒基因组和安普利康载体 - 一个更新
Matthieu Le Hars1, Charles Joussain1, Teddy Jégu2
1UMR U1179 INSERM - University of Versailles Saint Quentin en Yvelines (UVSQ)-Paris Saclay, Montigny-le-Bretonneux, France.
Gene therapy
|November 12, 2024
概括
简单疹病毒1型 (HSV-1) 衍生载体,包括非复制性基因组载体 (nrHSV-1) 和安普利康载体,对基因治疗具有前景. 虽然nrHSV-1载体在临床上取得了进展,但对安普利康载体的生产仍然存在挑战.
科学领域:
- 病毒学 病毒学
- 基因治疗 基因治疗
- 分子生物学分子生物学
背景情况:
- 简单疹病毒1型 (HSV-1) 已被改造成两个主要的缺陷载体类型:非复制性基因组载体 (nrHSV-1) 和安普利康载体.
- 了解HSV-1/载体生物学,包括抗病毒防御和表观遗传控制,对于载体的发展至关重要.
研究的目的:
- 审查由HSV-1衍生的nrHSV-1和amplicon载体的特征.
- 总结最近在HSV-1载体生物学和设计方面的进展.
- 评估这些载体类型的临床翻译状态和局限性.
主要方法:
- 对HSV-1衍生载体研究的文献综述.
- 对矢量设计,基因工程和生物特性进行分析.
- 评估临床试验进展和制造方面的挑战.
主要成果:
- 在nrHSV-1载体设计和HSV-1生物学方面的重大突破加速了它们的发展.
- nrHSV-1 载体具有较低的免疫性和增强的安全性,导致一些临床试验获得FDA 批准.
- 安普利康载体可以携带大型转基因并避免基因组稀释,但生产限制阻碍了临床翻译.
结论:
- 由于安全性和疗效的提高,nrHSV-1载体正在成功地向临床应用发展.
- 具有成本效益的,符合GMP的无助剂安普利康载体生产的挑战阻碍了它们的临床转化.
- 对安普利康载体制造的进一步研究是必要的,以实现它们的全部治疗潜力.
相关概念视频
00:59Gene Therapy
25.2K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.2K
01:29Microorganisms in Medicine and Therapeutics
1
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1